Impact of Rosuvastatin on Risk Markers of Venous Thromboembolism During Systemic Therapy for Advanced Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2016
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Pharmacodynamics
- Acronyms DISOLVE
- 07 Jun 2017 Biomarkers information updated
- 28 Dec 2015 Planned End Date changed from 1 Sep 15 to 1 Sep 2016 as reported by ClinicalTrials.gov.
- 28 Dec 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov.